Literature DB >> 17178348

Changes in matrix metalloproteinase 2 activities in amniochorions during premature rupture of membranes.

Atsuyuki Ota1, Hisashi Yonemoto, Akimasa Someya, Shigeru Itoh, Katsuyuki Kinoshita, Isao Nagaoka.   

Abstract

OBJECTIVE: Increased proteolytic activities of matrix metalloproteinases (MMPs) such as MMP-3 and MMP-9 are associated with premature rupture of membranes at term. However, it is unclear whether MMP-2 is involved in the premature rupture of membranes. In this study, to elucidate the role of MMP-2, we evaluated the activity of MMP-2 and also the expression of pro-MMP-2, membrane type 1 (MT1)-MMP and tissue inhibitor of metalloproteinase (TIMP)-1 in premature rupture of membranes.
METHODS: Amniochorions were prepared from 29 subjects with no labor (cesarean section; CS, n = 10), labor (normal delivery; ND, n = 10), and labor during premature rupture of membranes (PROM, n = 9). MMP-2 activity was spectrophotometrically assayed by measuring the digestion of an MMP-2-specific substrate. The levels of pro-MMP-2, MT1-MMP and TIMP-1 were determined by Western immunoblotting.
RESULTS: The activity of MMP-2 in PROM was significantly higher than that in CS and ND (P <.05). In addition, the levels of MT1-MMP, an activator of MMP-2, were higher in PROM than in CS and ND. In contrast, the level of TIMP-1, an inhibitor of MMP-2 was substantially lower in PROM than CS and ND. Moreover, the levels of pro-MMP-2 were increased more significantly in PROM and ND than in CS (P <.05).
CONCLUSION: Our results suggest that the increased expression of pro-MMP-2 and MT1-MMP and decreased expression of TIMP-1 may result in the increased activity of MMP-2, which is involved in the degradation of extracellular matrix (ECM) of fetal membrane, thereby inducing the premature rupture of membranes at term.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178348     DOI: 10.1016/j.jsgi.2006.10.001

Source DB:  PubMed          Journal:  J Soc Gynecol Investig        ISSN: 1071-5576


  7 in total

Review 1.  Extracellular matrix dynamics and fetal membrane rupture.

Authors:  Jerome F Strauss
Journal:  Reprod Sci       Date:  2012-01-19       Impact factor: 3.060

2.  In-vivo stretch of term human fetal membranes.

Authors:  E M Joyce; P Diaz; S Tamarkin; R Moore; A Strohl; B Stetzer; D Kumar; M S Sacks; J J Moore
Journal:  Placenta       Date:  2015-12-20       Impact factor: 3.481

3.  Modulation of amniotic fluid activin-a and inhibin-a in women with preterm premature rupture of the membranes and infection-induced preterm birth.

Authors:  Victor A Rosenberg; Irina A Buhimschi; Antonette T Dulay; Sonya S Abdel-Razeq; Emily A Oliver; Christina M Duzyj; Heather Lipkind; Christian M Pettker; Catalin S Buhimschi
Journal:  Am J Reprod Immunol       Date:  2011-10-13       Impact factor: 3.886

4.  High-risk human papillomavirus infection is associated with premature rupture of membranes.

Authors:  GeumJoon Cho; Kyung-Jin Min; Hye-Ri Hong; SuhngWook Kim; Jin-Hwa Hong; Jae-Kwan Lee; Min-Jeong Oh; HaiJoong Kim
Journal:  BMC Pregnancy Childbirth       Date:  2013-09-06       Impact factor: 3.007

5.  Vaginal Lactoferrin Modulates PGE2, MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations.

Authors:  Alessandro Trentini; Martina Maritati; Carlo Cervellati; Maria C Manfrinato; Arianna Gonelli; Carlo A Volta; Fortunato Vesce; Pantaleo Greco; Franco Dallocchio; Tiziana Bellini; Carlo Contini
Journal:  Mediators Inflamm       Date:  2016-10-31       Impact factor: 4.711

6.  Genetic polymorphisms of matrix metalloproteinases 1-3 and their inhibitor are not associated with premature labor.

Authors:  Konstantinos Lathouras; Srdjan Saso; Menelaos Tzafetas; Kallirroi Kalinderi; Styliani Fidani; Vassiliki Zournatzi; Maria Kyrgiou; Christina Fotopoulou; Sadaf Ghaem-Maghami; Ioannis Tzafetas
Journal:  Future Sci OA       Date:  2018-08-24

7.  Regulation of MT1-MMP/MMP-2/TIMP-2 axis in human placenta.

Authors:  Zoë L Vincent; Murray D Mitchell; Anna P Ponnampalam
Journal:  J Inflamm Res       Date:  2015-10-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.